Showing results (221-230 of 289) with videos related to

Sort By:
Pageof 29
The Journal of Clinical Investigation|November 29, 2016
Dual modulation of MCL-1 and mTOR determines the response to sunitinibMohamed Elgendy, Amal Kamal Abdel-Aziz, Salvatore Lorenzo Renne, et al.
Targeted Oncology|August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Expert Review of Anticancer Therapy|November 5, 2021
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)Alessia Mennitto, Emma Zattarin, Massimo Di Maio, et al.
Journal for Immunotherapy of Cancer|November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapyToni K Choueiri, Harriet Kluger, Saby George, et al.
Lancet (London, England)|June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialSumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Targeted Oncology|July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
The Oncologist|November 17, 2025
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysisFabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, et al.
Clinical Genitourinary Cancer|November 6, 2023
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Clinical Medicine Insights. Oncology|July 22, 2021
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, et al.
Plos One|April 18, 2015
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?Francesco Pantano, Matteo Santoni, Giuseppe Procopio, et al.
Pageof 29